Please assess the completion status of the following clinical trial:

Trial Title: Early Identification of Myocardial Impairment in PBC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for PBC group:~* Age between 18-80 years old.~* Definite primary biliary cirrhosis diagnosis which is consistent with European Association for the Study of the Liver (EASL) \[Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis (2017)\]. The following three diagnostic factors, at least meet two:~  1. History of elevated alkaline phosphatase (ALP) levels;~ 2. Liver biopsy consistent with PBC;~ 3. Positive antimitochondrial antibodies (AMA) or specific antinuclear antibodies;~* Providing written informed consent~Exclusion Criteria:~* History or presence of other concomitant liver disease including:~  1. cirrhosis or viral hepatitis;~ 2. Inherited metabolic liver disease;~ 3. Drug-induced liver injury;~ 4. Other systemic disease inducing liver change.~* Subjects with life expectancy \< 6 months.~* Subjects with known ischemic/non-ischemic cardiomyopathy or abnormal in cardiac-related examinations.~* Subjects with standard metallic contraindications to CMR (i.e., estimated glomerular filtration rate \< 30 ml/min/1.73 m2, New York Heart Association functional capacity class IV)~Inclusion Criteria for Control group:~* Absence of known systemic diseases~* Normal examinations in CMR/Echo/ECG~* Age between 18-80 years old.~* Providing written informed consent~Exclusion Criteria:~* Subjects with known heart disease including:~  1. Documented coronary artery disease;~ 2. Ischemia/non-ischemia cardiomyopathy;~ 3. Other systemic disease inducing heart change.~* Subjects with known liver disease including:~  1. Viral hepatitis;~ 2. Inherited metabolic liver disease;~ 3. Drug-induced liver injury;~ 4. Other systemic disease inducing liver change.~* Subjects with standard metallic contraindications to CMR

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- PBC group (Type: None): Patients have a definite PBC diagnosis.
- Control group (Type: None): The healthy volunteers.

Based on this trial design, predict the completion outcome and termination type (if applicable).